Parameters | Breast cancer (N = 3606) | Carboplatin-treated lung cancer (N = 4497) | Cisplatin-treated lung cancer (N = 1154) | |||
---|---|---|---|---|---|---|
Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | Regression coefficient (95% CI) | P value | |
Age | -0.0032 (-0.0219; 0.0155) | 0.7354 | -0.0008 (-0.0120; 0.0105) | 0.8961 | -0.0149 (-0.0325; 0.0027) | 0.0968 |
CCI | 0.2529 (0.0572; 0.4486) | 0.0113 | 0.0448 (0.0087; 0.0810) | 0.0151 | 0.0747 (0.0182; 0.1312) | 0.0096 |
Gender (male as reference) | ||||||
Female | NA | -0.1815 (-0.4202; 0.0573) | 0.1363 | -0.0132 (-0.3975; 0.3711) | 0.9463 | |
Days with cyclophosphamide (in breast cancer) or carboplatin (in lung cancer) treatment | -0.3800 (-0.5600; -0.2000) | <.0001 | -0.0483 (-0.0848; -0.0118) | 0.0095 | 0.0113 (-0.0263; 0.0488) | 0.5561 |
Antiemetic regimen (older 5-HT3 RAs as reference) | ||||||
Palonosetron | -0.6431 (-1.0391; -0.2471)* | 0.0015 | -0.3436 (-0.5871; -0.1001)* | 0.0057 | -0.0373 (-0.4456; 0.3711) | 0.8580 |